Host: The Japanese Society of Toxicology
Name : The 51st Annual Meeting of the Japanese Society of Toxicology
Date : July 03, 2024 - July 05, 2024
Norovirus is the leading cause of acute gastroenteritis worldwide. There is currently no effective vaccine against norovirus. The recent development of virus-like-particle (VLP), which have the same antigenic properties as noroviruses but lack genes for self-replication, has made it possible to develop a vaccine using VLP as antigens. This study aimed to compare the efficacy and adverse reactions of the antibody-producing capacity of VLPs with various adjuvants.
Mice were vaccinated intramuscularly with 2 injections of norovirus VLP with 8 different adjuvants, and plasma was collected dynamically for 7-10 weeks after vaccination to measure antibody titres by ELISA. Compared with the control VLP-treated group (without adjuvant), the adjuvant-added groups significantly increased the maximal antibody production and the duration of antibody production. However, some unfavorable effects were also observed in some of the adjuvant-added groups.
These results suggest that some adjuvants have the power to increase the antibody production efficiency of norovirus VLPs, albeit with some degree of side-effects. This study provides us with evidence to determine the optimized condition of adjuvant administration in combination with VLP based on efficacy and safety evaluations.
